Therapeutic aspects of cannabis and cannabinoids.
BACKGROUND
Review commissioned in 1996 by the Department of Health (DOH).


OBJECTIVE
Assess therapeutic profile of cannabis and cannabinoids.


METHODS
Medline search, references supplied by DOH and others, and personal communications.


CONCLUSIONS
Cannabis and some cannabinoids are effective anti-emetics and analgesics and reduce intra-ocular pressure. There is evidence of symptom relief and improved well-being in selected neurological conditions, AIDS and certain cancers. Cannabinoids may reduce anxiety and improve sleep. Anticonvulsant activity requires clarification. Other properties identified by basic research await evaluation. Standard treatments for many relevant disorders are unsatisfactory. Cannabis is safe in overdose but often produces unwanted effects, typically sedation, intoxication, clumsiness, dizziness, dry mouth, lowered blood pressure or increased heart rate. The discovery of specific receptors and natural ligands may lead to drug developments. Research is needed to optimise dose and route of administration, quantify therapeutic and adverse effects, and examine interactions.
Robson
P
P
Warneford Hospital, Oxford OX3 7JX, UK.
D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects; D002186:Cannabinoids / Q000627:therapeutic use*; D002188:Cannabis / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy; D006077:Government Agencies; D006801:Humans; D007880:Legislation, Drug; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009325:Nausea / Q000188:drug therapy*; D008517:Phytotherapy; D006113:United Kingdom
D018712:Analgesics, Non-Narcotic; D002186:Cannabinoids